Role of octreotide on release of intact 1-84 parathyroid hormone from human parathyroid cells

British Journal of Surgery

Volumn 85, Issue 8, 1998, Pages 1133-1137

  Sadler, G P ^a   Jones, D L ^a   Morgan, J M ^a   Neonakis, E ^a   Woodhead, J S ^a   Wheeler, M H ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; MESSENGER RNA; OCTREOTIDE; PARATHYROID HORMONE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ARTICLE; CELL CULTURE; CELL SUSPENSION; CHEMOLUMINESCENCE; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; HYPERPLASIA; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; PARATHYROID ADENOMA; PARATHYROID CELL; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL;

ADENOMA; CELLS, CULTURED; HORMONES; HUMANS; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; OCTREOTIDE; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; SOMATOSTATIN;

EID: 0031875564     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1998.00788.x     Document Type: Article

References (39)

1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179; 77-9.
2. Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495-501; 1556-63.
3. Elde RP, Parsons JA. Immunocytochemical localization of somatostatin in cell bodies of the rat hypothalamus. American Journal of Anatomy 1975; 144: 541-8.
4. Polak JM, Pearse AGE, Grimelius L, Bloom SR. Growth hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells. Lancet 1975; i: 1220-5.
5. Pradayrol L, Jornvall H, Mutt V, Ribet A. N-terminally extended somatostatin: the primary structure of somatostatin-28. FEBS Lett 1980; 109: 55-8.
6. Shen LP, Pictet RL, Rutter WJ. Human somatostatin 1: sequence of the cDNA. Proc Natl Acad Sci U S A 1982; 79: 4575-9.
7. Lucey MR. Endogenous somatostatin and the gut. Gut 1986; 27: 457-67.
8. Alberti KGMM, Christensen NG, Christensen SE, Hansen AP, Iversen J, Lundbaek K et al. Inhibition of insulin secretion by somatostatin. Lancet 1973; ii: 1299-301.
9. Mortimer CH, Tunbridge WM, Carr D, Yeomans L, Lind T, Coy DH et al. Growth-hormone-releasing-inhibiting hormone: effects on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet 1974; i: 697-701.
10. Alford FP, Bloom SR, Nabarro JDN, Hall R, Besser GM, Coy DH et al. Glucagon control of fasting glucose in man. Lancet 1974; ii: 974-7.
11. Kravetz D, Bosch J, Teres J, Bruix J, Rimola A, Rodes J. Comparison of somatostatin and vasopressin infusions in treatment of acute variceal hemorrhage. Hepatology 1984; 4: 442-6.
12. Jenkins SA, Baxter JN, Corbett W, Devitt P, Ware J, Shields R. A prospective randomised controlled clinical trial comparing somatostatin and vasopressin in controlling acute variceal haemorrhage. BMJ 1985; 290: 275-8.
13. Reisine T, Zhang YL, Sekura R. Pertussis toxin treatment blocks the inhibition of somatostatin and increases the stimulation by forskolin of cyclic AMP accumulation and adrenocorticotrophin secretion from mouse anterior pituitary tumor cells. J Phamacol Exp Ther 1985; 232: 275-82.
14. Lewis DL, Weight FF, Luini A. A guanine nucleotide-binding protein mediates the inhibition of voltage-dependent calcium current by somatostatin in a pituitary cell line. Proc Natl Acad Sci U S A 1986; 83: 9035-9.
15. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 1992; 89: 251-5.
16. Yamada Y, Reisine T, Law SF, Ihara Y, Kubota A, Kagimoto S et al. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 1992; 6: 2136-42.
17. Xu Y, Song J, Bruno JF, Berelowitz M. Molecular cloning and sequencing of a human somatostatin receptor, hSSTR4. Biochem Biophys Res Commun 1993; 193: 648-52.
18. Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 1993; 195: 844-52.
19. Rohrer L, Raulf F, Bruns C, Buettner B, Hofstaedter F, Schule R. Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci U S A 1993; 90: 4196-200.
20. Bauer W, Briner U, Doepfner W, Marbach P, Petcher TJ, Pies J. Octreotide (Sandostatin SMS 201-995): its structure and pharmacology. ASAP Newsletter 1990; 8: 1-3.
21. Sassolas G. The role of Sandostatin in acromegaly. Metabolism 1992; 41(Suppl 2): 39-43.
22. Saari A, Schroder T, Kivilaakso E, Kalima T, Lempinen M. Treatment of pancreatic fistulas with somatostatin and total parenteral nutrition. Scand J Gastroenterol 1989; 24: 859-62.
23. Vinik AI, Thompson N, Eckhauser F, Moattari AR. Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. Acta Oncol 1989; 28: 389-402.
24. McKee R. A study of octreotide in oesophageal varices. Digestion 1990; 45(Suppl 1): 60-5.
25. Deftos LJ, Lorenzi M, Bohanon N, Tsalakian E, Schneider V, Gerich JE. Somatostatin does not suppress plasma parathyroid hormone. J Clin Endocrinol Metab 1976; 43: 205-7.
26. Hargis GK, Williams GA, Reynolds WA, Chertow BS, Kukreja SC, Bowser EN et al. Effect of somatostatin on parathyroid hormone and calcitonin secretion. Endocrinology 1978; 102: 745-50.
27. Lucarotti ME, Hamilton JA, Farndon JR. Somatostatin and primary hyperparathyroidism. Br J Surg 1994; 81: 1141-3.
28. Zielke A, Hasse C, Bruns C, Sitter H, Rothmund M. Octreotide: effective treatment for hyperparathyroidism? A prospective, randomized, controlled clinical trial. Surgery 1997; 121: 606-10.
29. Hasse C, Zielke A, Bruns C, Kunneke M, Ehlenz K, Bachem MG et al. Influence of somatostatin to biochemical parameters in patients with primary hyperparathyroidism. Exp Clin Endocrinol Diabetes 1995; 103: 391-7.
30. Brown EM, Hurwitz S, Aurbach GD. Preparation of viable isolated bovine parathyroid cells. Endocrinology 1976; 99: 1582-8.
31. Battershill PE, Clissold SP. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989; 38: 658-702.
32. Brown RC, Aston JP, Weeks I, Woodhead JS. Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay. J Clin Endocrinol Metab 1987; 65: 407-14.
33. Hoyer D, Lubbert H, Bruns C. Molecular pharmacology of somatostatin receptors. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 441-53.
34. Farquharson M, Harvie R, McNicol AM. Detection of mRNA using a digoxigenin end labelled oligodeoxynucleotide probe. J Clin Pathol 1990; 43: 424-8.
35. Parfitt AM, Willgoss D, Jacobi J, Lloyd HM. Cell kinetics in parathyroid adenomas: evidence for decline in rates of cell birth and tumour growth, assuming clonal origin. Clin Res 1989; 37: 458A.
36. Weber CJ, Marangos PJ, Richardson S, Lo Gerfo P, Hardy MA, Feind C et al. Presence of neuron-specific enolase and somatostatin in human parathyroid tissues. Surgery 1985; 98: 1008-12.
37. Weber CJ, O'Dorisio TM, Howe B, D'Agati V, Ward L, Russell J et al. Vasoactive intestinal polypeptide-, neurotensin-, substance P-, gastrin-releasing peptide-, calcitonin-, calcitonin gene related peptide-, and somatostatin-like immunoreactives in human parathyroid glands. Surgery 1991; 110: 1078-85.
38. Botana MA, Castillo L, Pesquera C, Freijanes J, Amado JA, Gonzalez-Macias J. Lack of effect of octreotide on parathyroid hormone levels and urinary excretion of epidermal growth factor. Horm Metab Res 1993; 25: 37-9.
39. Nutting DF, Schriock EA, Palmieri GM, Bittle JB, Elmendorf BJ, Horner LH et al. Octreotide enhances positive calcium balance in Duchenne muscular dystrophy. Am J Med Sci 1995; 310: 91-8.